Clinical Trial Update: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum [Phase 2]

View source ↗

Summary

This Phase 2 study reports results on alpelisib (BYL719) for PIK3CA-related overgrowth spectrum (PROS) in pediatric and adult patients, assessing efficacy, safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pik3ca-related Overgrowth Spectrum

Drugs mentioned

• Alpelisib (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: PIK3CA-related Overgrowth Spectrum (PROS) | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-10